Analysts’ Weekly Ratings Updates for Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals (NASDAQ: CTXR) recently received a number of ratings updates from brokerages and research firms:

• 12/29/2025 – Citius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/27/2025 – Citius Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating.
• 12/22/2025 – Citius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Citius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Citius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Citius Pharmaceuticals had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $6.00 price target on the stock.
• 12/1/2025 – Citius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Citius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Citius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Citius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.